疏风解毒胶囊联合α-干扰素和阿比多尔治疗普通型新型冠状病毒肺炎的疗效和安全性分析

Efficacy and Safety Analysis of Shufeng Jiedu Capsules Combined with Interferon Alpha Plus Arbidol in the Treatment of Common COVID-19

【目的】研究疏风解毒胶囊联合α-干扰素和阿比多尔治疗普通型新型冠状病毒肺炎的疗效和安全性。【方法】将100例普通型新型冠状病毒肺炎患者随机分为观察组和对照组,每组各50例。对照组患者给予α-干扰素联合阿比多尔片抗病毒治疗,观察组在对照组基础上加用疏风解毒胶囊治疗,疗程为2周。观察2组患者治疗前后白细胞计数和淋巴细胞百分比的变化情况,比较2组患者的核酸转阴时间、症状消退时间、肺部影像学改善情况、药物过敏和相关不良反应发生情况。【结果】(1)治疗后,观察组患者的核酸转阴时间为(6.42±1.02)d,短于对照组的(7.37±0.94)d,差异有统计学意义(P<0.05)。(2)治疗后,观察组患者的肺部病灶开始吸收时间较对照组明显缩短,肺部病灶完全吸收率较对照组明显提高,差异均有统计学意义(P<0.05);同时,在观察过程中,2组患者均未进展为重型或者危重型。(3)治疗后,观察组患者的发热消退时间较对照组缩短,差异有统计学意义(P<0.05);而2组患者的流涕、鼻塞、头晕、乏力、咳嗽等症状消退时间比较,差异均无统计学意义(P>0.05)。(4)治疗后,2组患者的白细胞计数和淋巴细胞百分比均较治疗前升高(P<0.05),且观察组的升高作用均优于对照组,差异均有统计学意义(P<0.05)。(5)研究过程中,2组患者的药物过敏和相关不良反应发生率均为8.0%(4/50),差异无统计学意义(P>0.05)。【结论】疏风解毒胶囊联合α-干扰素和阿比多尔治疗普通型新型冠状病毒肺炎患者疗效显著,其疗效优于单纯西药治疗。

Objective To study the efficacy and safety of Shufeng Jiedu Capsules combined with interferon alpha(IFN-α)and arbidol in the treatment of common coronavirus disease 2019(COVID-19).Methods A total of100 patients with common COVID-19 were randomly divided into observation group and control group,50 patients in each group.The control group was treated with IFN-αcombined with arbidol tablets for antiviral therapy,and the observation group was treated with Shufeng Jiedu Capsules combined with IFN-αand arbidol tablets,the course of treatment lasting 2 weeks.The changes of white blood cell(WBC)count and lymphocyte percentage in the two groups were observed before and after treatment,and the nucleic acid negative-conversion time,symptom resolution time,lung imaging improvement,drug allergy and related adverse reaction of the two groups were compared.Results(1)After treatment,the nucleic acid negative-conversion time of the observation group was(6.42±1.02)days,which was shorter than that of the control group[(7.37±0.94)days],the difference being statistically significant(P<0.05).(2)After treatment,the initial absorption time of lung lesions showed by lung imaging was significantly shortened and the complete absorption rate of lung lesions was significantly increased in the observation group compared with those in the control group,the differences being statistically significant(P<0.05).During the observation period,none of the patients in the two groups progressed in the severe type or critical type.(3)After treatment,the fever resolution time in the observation group was shortened compared with that in the control group,the difference being statistically significant(P<0.05).But the differences were not statistically significant in the resolution time of runny nose,nasal obstruction,dizziness,fatigue,cough and other symptoms between the two groups(P>0.05).(4)After treatment,WBC count and the percentage of lymphocytes in the two groups were increased compared with those before treatment(P<0.05),and the improvement in the observation group was superior to that in the control group,the difference being statistically significant(P<0.05).(5)During the trial,the incidence of drug allergy and related adverse reaction in both groups was 8.0%(4/50),without statistically significant difference(P>0.05).Conclusion Shufeng Jiedu Capsules combined with IFN-αplus arbidol exert significant effect in treating common COVID-19,and the combined therapy is superior to western medicine alone.